According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide, ranking among the top three most common cancers in 19 countries, Bhutan, Kyrgyzstan, Cape Verde, and Tajikistan are the 4 most affected countries. Gastric cancer is responsible for about one in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed worldwide.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market
Data Bridge Market Research analyses that the Global Gastric Cancer Diagnostics Market is expected to grow at a CAGR of 8.7% in the forecast period of 2023 to 2030 and is expected to reach USD 1,950.82 million by 2030. The high adoption of gastric cancer diagnostics in various healthcare sectors is projected to propel the market's growth as they create and maintain workflow optimization and help in visitor management and fall & detection prevention for the safety of patients.
Rise in alcohol consumption and surge in smoking is expected to drive the market's growth
Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone, representing a severe public health issue that warrants further investigation.
A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.
The above instances show the relation between smoking and alcohol consumption as a risk factor for gastric cancer. Thus, the rise in alcohol consumption and surge in smoking is expected to drive the global gastric cancer market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Confirmatory Test, Gastric Cancer Screening Tests/Physical Exam), Age Group (Adult, Pediatric, and Geriatrics), Disease Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E, Israel, Egypt, and rest of Middle East and Africa.
|
|
Market Players Covered
|
BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics., Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global gastric cancer diagnostics market is categorized into nine notable segments which are based on the product type, diagnostics type, age group, type, stage, gender, sample type, end users, and distribution channel.
- On the basis of product type, the global gastric cancer diagnostics market is segmented into instruments, reagents & consumables, and services.
In 2023, the reagents & consumables of type segment is anticipated to dominate the global gastric cancer diagnostics market
In 2023, the reagents & consumables segment of this market is expected to dominate the global gastric cancer diagnostics market owing to the increasing number of product launches, due to which a wide range of kit products are available in the market. Moreover, IVD players are also focusing on the development of more advanced kits. The reagents & consumables segment is expected to reach the highest CAGR of 9.8% in the forecast period of 2023-2030.
- On the basis of diagnostics type, the global gastric cancer diagnostics market is segmented into confirmatory test and gastric cancer screening tests/physical exam. In 2023, the confirmatory tests segment is expected to dominate the gastric cancer diagnostics market with a 57.45% market share because most of the diagnostics have been done with imaging techniques such as endoscopic ultrasonography, PET-CT scan, and CT scan
- On the basis of age group, the global gastric cancer diagnostics market is segmented into adult, pediatric, and geriatrics. In 2023, the geriatrics segment is expected to dominate the gastric cancer diagnostics market with a 52.95% market share because the geriatric population is vulnerable to stomach cancer more often
- On the basis of type, the global gastric cancer diagnostics market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, Gastrointestinal Stromal Tumor (GIST), gastric lymphoma, and others. In 2023, the intestinal or diffuse adenocarcinoma segment is expected to dominate the gastric cancer diagnostics market with a 39.52% market share because of the increase in the prevalence of intestinal or diffuse adenocarcinoma type of stomach cancer
- On the basis of stage, the global gastric cancer diagnostics market is segmented into stage 0, stage I, stage II, and stage III. In 2023, the stage I segment is expected to dominate the gastric cancer diagnostics market with a 36.70% market share because a number of the confirmatory tests performed at stage I only to diagnose stomach cancer
- On the basis of gender, the global gastric cancer diagnostics market is segmented into male and female. In 2023, the male segment is expected to dominate the gastric cancer diagnostics market with a 53.37% market share because men are more likely to develop stomach cancer due to smoking, drinking, and consumption of tobacco
- On the basis of sample type, the global gastric cancer diagnostics market is segmented into blood, tissue, urine, and stool. In 2023, the stool segment is expected to dominate the gastric cancer diagnostics market with a 49.06% market share because most of the diagnostics are performed from stool samples as well as the availability of stool diagnostic products with companies
- On the basis of end users, the global gastric cancer diagnostics market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.
In 2023, the hospitals segment is projected to hold the largest share of end-user segment in the gastric cancer diagnostics market
In 2023, the hospitals segment holds the maximum market share as a higher number of patients prefer to visit hospitals for different cases, such as chronic diseases. The hospital segment is growing with a CAGR of 10.4 % in the forecast period of 2021 to 2028.
- On the basis of distribution channel, the global gastric cancer diagnostics market is segmented into direct tender and retail sales. In 2023, the direct tender segment is expected to dominate the gastric cancer diagnostics market with a 63.24% market share as direct tender enables large-scale medical product sales to increase the efficiency of end-user business growth by alerting and working on the most suitable contract opportunities
Major Players
Some of the major companies providing global gastric cancer diagnostics in the global gastric cancer diagnostics market are BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics., Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others.
Market Development
- In February 2023, Johnson Controls and Willow announced a global partnership to digitally transform buildings and facilities into healthier, safer, more sustainable places for their clients and occupants. Johnson Controls and Willow have committed to working together to offer clients next-generation solutions. Digital twins can be especially helpful for evaluating huge datasets and forecasting patterns and trends. They play an increasingly significant role in the design, construction, and continuous operation of healthy structures and services. This prompted the company to grow its clientele
- In July 2021, DiaSorin S.p.A. announced that it had acquired Luminex Corporation in the U.S., leading to the strengthening of its product portfolio along with its presence in the region. This strategic initiative taken by the company has increased its sales in the market.
- In March 2020, Thermo Fisher Scientific Inc. announced that it had signed an agreement with Janssen Pharmaceutical Companies of Johnson & Johnson in order to mutually develop Companion Diagnostic (CDx) in oncology. This agreement by the company will strengthen its position in the field of oncology diagnostics leading to increased demand for its product in the future
- In March 2020, Thermo Fisher Scientific Inc. announced acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company has increased its product portfolio in the market, which will lead to increased revenue in the future
- In November 2019, Agilent Technologies, Inc. announced that it had received two Life Science Industry Awards (LSIA) for the 'Most Innovative New Products in 2019 from BioInformatics Inc. These awards received by the company have increased its credibility in the market, leading to increased sales of its products
- In April 2019, F. Hoffmann-La Roche Ltd announced that it had launched its new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer. This new product launched by the company has increased its demand and sales in the market
Regional Analysis
Geographically, the countries covered in the gastric cancer diagnostics market report are U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global gastric cancer diagnostics market during the forecast period 2023 -2030
In 2023, North America segment is expected to dominate the global gastric cancer diagnostics market with a 43.24% market share. This is due to the growing adoption of advanced technology and the launch of new products in this region. Additionally, the increasing number of cases of chronic wounds and the rising geriatric population are expected to further enhance the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest growing region in gastric cancer diagnostics market the forecast period 2023-2030
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development of medical facilities in emerging economies in this region. In addition to this, rising level of healthcare expenditure and increasing per-capita income are expected propel the market's growth rate in this region.
For more detailed information about the global gastric cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market
